JP5718638B2 - 新規な組成物、方法および使用 - Google Patents

新規な組成物、方法および使用 Download PDF

Info

Publication number
JP5718638B2
JP5718638B2 JP2010518606A JP2010518606A JP5718638B2 JP 5718638 B2 JP5718638 B2 JP 5718638B2 JP 2010518606 A JP2010518606 A JP 2010518606A JP 2010518606 A JP2010518606 A JP 2010518606A JP 5718638 B2 JP5718638 B2 JP 5718638B2
Authority
JP
Japan
Prior art keywords
albumin
seq
polypeptide
binding
binding polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010518606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534486A5 (enExample
JP2010534486A (ja
Inventor
ラッス・アブラフムセン
アンドレアス・ヨンソン
ヤコブ・ドーガン
ペル−オーケ・ニューグレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Publication of JP2010534486A publication Critical patent/JP2010534486A/ja
Publication of JP2010534486A5 publication Critical patent/JP2010534486A5/ja
Application granted granted Critical
Publication of JP5718638B2 publication Critical patent/JP5718638B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010518606A 2007-07-31 2008-07-17 新規な組成物、方法および使用 Active JP5718638B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96261807P 2007-07-31 2007-07-31
US60/962,618 2007-07-31
EP07113533.9 2007-07-31
EP07113533 2007-07-31
PCT/EP2008/059389 WO2009016043A2 (en) 2007-07-31 2008-07-17 New albumin binding compositions, methods and uses

Publications (3)

Publication Number Publication Date
JP2010534486A JP2010534486A (ja) 2010-11-11
JP2010534486A5 JP2010534486A5 (enExample) 2011-08-18
JP5718638B2 true JP5718638B2 (ja) 2015-05-13

Family

ID=40057660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518606A Active JP5718638B2 (ja) 2007-07-31 2008-07-17 新規な組成物、方法および使用

Country Status (11)

Country Link
US (2) US8937153B2 (enExample)
EP (2) EP2190863B1 (enExample)
JP (1) JP5718638B2 (enExample)
CN (2) CN104710518A (enExample)
AU (1) AU2008281913B2 (enExample)
CA (1) CA2694139C (enExample)
DE (1) DE08786222T1 (enExample)
DK (1) DK2190863T3 (enExample)
ES (1) ES2346178T3 (enExample)
HK (1) HK1211040A1 (enExample)
WO (1) WO2009016043A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008281913B2 (en) * 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
US20120134984A1 (en) * 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
DK2544785T3 (en) * 2010-03-08 2016-01-18 Ge Healthcare Bio Sciences Ab Immunoglobulin G Fc region binding polypeptide
JP5827218B2 (ja) * 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
WO2012004384A2 (en) * 2010-07-09 2012-01-12 Affibody Ab Polypeptides
CA2807127C (en) * 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
EA201390450A1 (ru) * 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
PT2621515T (pt) * 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
WO2012162068A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
CN104271588B (zh) * 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
KR20140142298A (ko) * 2012-03-28 2014-12-11 애피바디 에이비 경구투여
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
US9156887B2 (en) 2012-05-25 2015-10-13 Janssen Biotech, Inc. Non-natural consensus albumin binding domains
WO2014048977A1 (en) * 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
WO2014053586A1 (en) 2012-10-05 2014-04-10 Affibody Ab Her3 binding polypeptides
ES2639099T3 (es) * 2012-10-25 2017-10-25 Affibody Ab Polipéptido de unión a albúmina
PL2912051T3 (pl) 2012-10-25 2018-08-31 Affibody Ab Sposób rozdzielania białek zawierających domenę wiążącą albuminę
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
HK1218534A1 (zh) 2013-03-14 2017-02-24 多伦多大学管理委员会 支架化肽文库以及其制备和筛选方法
EP2968490A1 (en) 2013-03-14 2016-01-20 Daiichi Sankyo Co., Ltd. Novel binding proteins for pcsk9
KR102191654B1 (ko) 2013-03-15 2020-12-16 애피바디 에이비 신규 폴리펩티드
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014314214C1 (en) 2013-08-28 2019-01-24 Affibody Ab Binding polypeptides having a mutated scaffold
JP6767865B2 (ja) 2013-08-28 2020-10-14 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合する安定なポリペプチド
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
UA123432C2 (uk) 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
EP3193930B1 (en) 2014-09-17 2019-06-19 Affibody AB New polypeptides
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
MD20170035A2 (ro) 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
PT3245224T (pt) 2015-01-12 2020-10-08 Affibody Ab Polipéptidos de ligação a il-17a
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2994279A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN107022031A (zh) * 2016-01-29 2017-08-08 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白HSA1-Vβ1及其应用
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
CN107952080A (zh) * 2016-10-14 2018-04-24 中国科学院过程工程研究所 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
WO2019147954A1 (en) * 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2019175176A1 (en) 2018-03-13 2019-09-19 Affibody Ab Polypeptides based on a novel scaffold
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US20210316007A1 (en) * 2018-09-07 2021-10-14 Duke University Nanoparticulate drug delivery systems
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4017521A1 (en) 2019-09-02 2022-06-29 Biotest AG Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
US20220389066A1 (en) 2019-11-05 2022-12-08 Affibody Ab Polypeptides
EP4106798A1 (en) 2020-02-17 2022-12-28 Biotest AG Subcutaneous administration of factor viii
EP3878515A1 (en) * 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
CA3200702A1 (en) 2020-12-21 2022-06-30 Affibody Ab New polypeptide
WO2022171892A1 (en) 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
CN118632866A (zh) 2022-02-08 2024-09-10 阿菲博迪公司 结合胸腺基质淋巴细胞生成素的蛋白质z变体及其医疗用途
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados
TW202416938A (zh) 2022-08-10 2024-05-01 日商興和股份有限公司 親和體微胞(affibody micelle)藥物複合體
EP4665755A1 (en) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
AU2024265436A1 (en) 2023-05-04 2025-11-06 Affibody Ab New polypeptide
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
TW202545983A (zh) 2024-01-25 2025-12-01 瑞典商艾菲博迪公司 新穎多肽
CN121041473A (zh) * 2024-05-29 2025-12-02 烟台蓝纳成生物技术股份有限公司 一种双功能性融合蛋白、放射性核素标记物及其应用
CN118666961B (zh) * 2024-08-23 2024-11-26 通化安睿特生物制药股份有限公司 人白蛋白特异结合多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
GB9911287D0 (en) * 1999-05-14 1999-07-14 Affibody Technology Sweden Ab Self-assembling protein structures
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) * 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2008281913B2 (en) * 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド

Also Published As

Publication number Publication date
EP2546261A3 (en) 2013-08-14
ES2346178T1 (es) 2010-10-13
US20150158916A1 (en) 2015-06-11
CA2694139C (en) 2018-06-05
JP2010534486A (ja) 2010-11-11
WO2009016043A3 (en) 2009-06-04
DE08786222T1 (de) 2010-11-25
US10118949B2 (en) 2018-11-06
EP2546261A2 (en) 2013-01-16
US20100273979A1 (en) 2010-10-28
DK2190863T3 (en) 2015-11-30
AU2008281913A1 (en) 2009-02-05
US8937153B2 (en) 2015-01-20
ES2346178T3 (es) 2015-11-02
CA2694139A1 (en) 2009-02-05
WO2009016043A2 (en) 2009-02-05
CN104710518A (zh) 2015-06-17
EP2190863A2 (en) 2010-06-02
CN101765608B (zh) 2015-03-11
HK1211040A1 (en) 2016-05-13
AU2008281913B2 (en) 2013-11-07
EP2190863B1 (en) 2015-09-02
CN101765608A (zh) 2010-06-30

Similar Documents

Publication Publication Date Title
JP5718638B2 (ja) 新規な組成物、方法および使用
JP6590695B2 (ja) アルブミン結合ポリペプチド
AU2011275766B2 (en) Polypeptides
CN103459415B (zh) 设计的与血清白蛋白结合的重复蛋白
JPWO2018230257A1 (ja) ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
DK2912054T3 (en) Albumin-binding polypeptide
WO2024084203A1 (en) Single domain antibodies binding to albumin
JP7588427B2 (ja) 半減期が延長した薬物およびそのライブラリー、ならびに製造方法と使用
WO2024074762A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
Park et al. Single-chain variable fragments targeting domain II of human serum albumin for enhanced circulatory half-life via albumin association
Järver et al. Chemical synthesis and evaluation of a backbone‐cyclized minimized 2‐helix Z‐domain
HK40059771A (en) Designed repeat proteins binding to serum albumin
HK40012160B (en) Designed repeat proteins binding to serum albumin
HK40012160A (en) Designed repeat proteins binding to serum albumin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130917

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150319

R150 Certificate of patent or registration of utility model

Ref document number: 5718638

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250